Toolbox: Current phase III clinical trials Tiffany-Jade Kreys, PharmD1 1Assistant Professor of Pharmacy Practice University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas KEYWORDS clinical trials, depression, bipolar, schizophrenia, medications Table 1. Novel Agents for Major Depression, Bipolar Disorder, and/or Schizophrenia Product Name Sponsor Indication Mechanism of Action (previous name) Downloaded from http://meridian.allenpress.com/mhc/article-pdf/2/6/138/2094102/mhc_n129046.pdf by guest on 26 September 2021 Amitifadine Euthymics MDD Triple Reuptake Inhibitor (EB-1010) Bioscience (1:2:8 ratio of serotonin: norepinephrine: dopamine inhibition) Bitopertin Roche Schizophrenia Glycine reuptake inhibitor (RG1678) Enhances NMDA receptor activity Brexpiprazole Lundbeck MDD, Claimed to have "broad activity across multiple monoamine (OPC-34712) Otsuka America Schizophrenia systems and exhibits reduced partial agonist activity at D2 Pharmaceuticals receptors and enhanced affinity for specific serotonin receptors" Cariprazine Forest Laboratories BPAD, MDD adjunct D3-preferring/D2 receptor partial agonist (RGH-188) therapy, Schizophrenia Citalopram/ PharmaNeuro- MDD 5HT2A/D4 antagonist Pipamperone Boost (PNB01) Edivoxetine Eli Lilly MDD adjunct therapy Norepinephrine reuptake inhibitor (LY2216684) Vortioxetine Lundbeck MDD In vitro studies: 5HT3 and 7 receptor antagonist, 5HT1B partial (LUAA21004) Takeda agonist, 5HT1A agonist, serotonin transporter inhibitor Pharmaceuticals In vivo: Increases serotonin, norepinephrine, dopamine, USA acetylcholine, and histamine Table 2. New Formulations, Indications, and/or Stereoisomers of Existing Medications for Major Depression, Bipolar Disorder, and/or Schizophrenia Brand Name Sponsor Indication Mechanism of Action (generic) Abilify® IM depot Lundbeck Schizophrenia D2 and 5HT1A partial agonist, 5HT2A (aripiprazole) Otsuka America antagonist Pharmaceutical Nuvigil Cephalon Bipolar Depression Unknown (armodafinil) Korlym™ Corcept Therapeutics Psychotic Major Depression Glucocorticoid receptor antagonist (mifepristone) Latuda® Sunovion Bipolar Depression, MDD D2, 5HT2A, and 5HT7 antagonist; 5HT1A partial (lurasidone) Pharmaceuticals with mixed features agonist Levomilnacipran Forest Laboratories MDD Selective serotonin-norepinephrine reuptake inhibitor ® Vyvanse Shire Pharmaceuticals Bipolar Depression, MDD Dextroamphetamine prodrug (lisdexamfetamine) Norepinephrine and dopamine reuptake blocker Increases release of monoamines *For a complete list of references, see: Kreys T-J. Editorial-The Future of Psychotropics: Did Santa Forget about Mental Illness?. Ment Health Clin [Internet]. 2012;2(6):20. Available from: http://dx.doi.org/10.9740/mhc.n129045 Abbreviations: Major Depressive Disorder (MDD), Bipolar Affective Disorder (BPAD), serotonin (5HT), dopamine (D) How to cite this editor-reviewed article Kreys T-J. Toolbox: Current phase III clinical trials. Ment Health Clin [Internet]. 2012;2(6):138. Available from: http://dx.doi.org/10.9740/mhc.n129046 Mental Health Clinician, December 2012, Vol. 2, Issue 6 138 .